BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Novartis enters into research collaboration with Morphochem for use of its MOREsystem™ in lead discovery

Munich , Germany , 8 December 2003 Morphochem AG, a leader in the evolutionary discovery of small molecule drugs, has entered into a research collaboration with Novartis wherein Morphochem will apply MOREsystem™, its evolutionary drug discovery engine, to the discovery and optimisation of novel compounds with activity against a number of undisclosed biological targets for a range of health disorders or diseases.  Under the terms of the agreement, which were not disclosed, Novartis will fund the research at Morphochem and Morphochem is entitled to receive research and development milestone payments. Additionally Morphochem will retain the rights to develop compounds synthesised during the programme for which Novartis does not exercise a licence.

 

Dr Peter Seufer-Wasserthal, VP Business Development at Morphochem, commented: “This collaboration nicely fits our vision of working with partners to apply our integrated discovery technologies in parallel on a number of targets to identify compounds active against these targets. These compounds will then be further refined applying genetic algorithms in an evolutionary way in which multi parametric optimisation is used to identify compounds suited as potential drug candidates.”

 

-ends-

 

Morphochem AG discovers and develops highly selective small molecule compounds for the medicines of tomorrow. The company integrates novel chemistries with biological screening on the basis of its proprietary MolMind™ technology. Its unique and highly integrated chemical genomics platform provides a continuous flow of novel drug candidates for unmet medical needs in major areas of indications such as cancer and anti-infectives

 

Morphochem was founded in Munich in 1996 and is an integrated, transnational drug discovery and development company, currently employing some 100 staff. To date the Company has raised €78 million in four financing rounds. For further information please consult www.morphochem.com.

 

For further information, please contact:

Morphochem: Thomas Loeser, CFO, tel: +49 (0)89 78 00 50, email: thomas.loeser@morphochem.de

 

Dr Peter Seufer-Wasserthal, VP Business Development, tel: +43 (0)7673 321511, email: peter.seufer@morphochem.de  

 

Media enquiries: Sue Charles, CEO Northbank Communications, tel: +44 (0)20 7886 8152, email: s.charles@northbankcommunications.com

 
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.